Stay updated on Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial
Sign up to get notified when there's something new on the Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial page.

Latest updates to the Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe record for the completed DUO Phase 3 trial is displayed, including its treatments, eligibility criteria, study locations, outcomes, and linked study documents.SummaryDifference72%

- Check17 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check24 days agoChange DetectedA sitewide notice announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now displays a 403 Forbidden error with a visible 403 label and a Home button, indicating that access to the page is blocked. This reflects an access-control state change rather than updates to the page's substantive content.SummaryDifference0.5%

Stay in the know with updates to Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib vs Ofatumumab in CLL/SLL Clinical Trial page.